OBSERVATIONS AND KEY TAKEAWAYS FROM RNS DATED 01 & 26-Mar-202126 Apr 2021 02:15
I) Observations and Key Takeaways from RNS dated 01-Mar-2021:
a) Trevor Brown, CEO of Braveheart stated that, “ BRH is look forward to providing the next update in April.” In another place of the RNS states further updates to be made by end of April.
In general, good positive RNSs are posted on Mondays at 7:00AM and negative RNSs posted on Fridays. Thus, expectation is still positive RNS tomorrow at 7:00AM.
b) Successful Clinical Validation results within MHRA specification limits;
c) Obtain CE Mark for the Test with larger number of patient samples;
d) Platform technology to detect new viruses and variants of COVID-19;
e) Prof Carl Smythe commented, "We are very pleased with the performance of the system to date and we expect additional improvements in accuracy as we optimise software."
f) Trevor Brown commented, "These latest laboratory results make clear that the Paraytec technology is capable of being market leading, and also said, our attention will now turn towards quickly commencing the final clinical trial and commercialising our product either ourselves or with a partner.
II) Observations and Key Takeaways from RNS dated 26-Mar-2021:
a) Optimised the operational sensitivity of its instrument for the detection of pre-symptomatic and early-stage symptomatic virus levels. Using this approach, the team has established a lower limit of detection of 1,000 virions per millilitre of sample fluid analysed, as anticipated.
b) Paraytec's test requires only 0.1 millilitres of sample fluid to undertake a successful test, and
c) Our attention will now turn towards quickly commencing the final clinical trial and commercialising our product either ourselves or with a partner.
d) Paraytec test may be capable of detecting as few as 100 virions in a sample. This would represent a significantly better performance than the lateral flow tests that are currently authorised for emergency use to detect infectivity and which typically have a lower limit of detection of 10,000-100,000 virions per sample.
e) If confirmed in the prospective clinical validation, it would mean that Paraytec's test would result in a substantial (40%) improvement in overall test sensitivity compared to existing lateral flow tests, due to the reduced chances of receiving a false negative result and thus ensuring that people who obtain a negative test result can be increasingly confident that they have not become infected.
f) Prof Carl Smythe commented, "The analytical sensitivity achieved in these latest set of tests is very good news indeed. Having the capability to detect a few hundred viral copies per swab means that this test - which does not need to be located in a specialised laboratory or operated by trained laboratory personnel.
g) Trevor Brown commented "These results have exceeded even our ambitious expectations and are a credit to Professor Smythe and his tireless team."
bbrq648
Sign In
Follow the stocks
